Sinopharm Group Co. Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SHTDY research report →
Price Chart
About the company
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products.
- CEO
- Wanyong Lian
- IPO
- 2016
- Employees
- 94,910
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on SHTDY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.92B
- P/E
- 5.58
- PEG
- 1.74
- P/S
- 0.07
- P/B
- 0.46
- EV/EBITDA
- 5.40
- Div Yield
- 5.37%
- Gross Margin
- 7.03%
- Op Margin
- 2.95%
- Net Margin
- 1.24%
- ROE
- 8.33%
- ROIC
- 5.57%
Latest fiscal year · YoY change
- Revenue
- $559.50B-4.3%
- Gross Profit
- $40.09B-9.4%
- Op Income
- $16.21B
- Net Income
- $6.96B-1.3%
- EPS
- $11.10-1.8%
- OCF Growth
- +22.5%
- FCF Growth
- +30.7%
- 52W High
- $14.87
- 52W Low
- $9.00
- 50D MA
- $10.06
- 200D MA
- $11.71
- Beta
- 0.45
- RSI (14)
- 40
- Avg Volume
- 150.75K
No earnings-call transcripts are available for SHTDY yet.
- Free Float
- 40.8%
- Shares Outstanding
- 624.14M
- Float Shares
- 254.92M
Congressional trading
Senate and House stock disclosures for SHTDY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Sheri BiggsHouse · SC03 | Sell | Mar 18, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 1 ETFs
Biggest fund positions in SHTDY by dollar value.
Our SHTDY coverage
Recent articles, reports, and earnings notes.
No research on SHTDY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SHTDY report →Sinopharm Group (OTCMKTS:SHTDY) and Pediatrix Medical Group (NYSE:MD) Financial Survey
defenseworld.net · Sep 4
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
accessnewswire.com · Mar 19
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
prnewswire.com · Dec 17
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts
prnewswire.com · Nov 25
Pandemic Accelerates China's Drive Into mRNA Treatments
seekingalpha.com · Jun 18
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
seekingalpha.com · May 10
Diversifying Into Top-Ranked Sinopharm
seekingalpha.com · Apr 25
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
seekingalpha.com · Apr 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.